Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study
Abstract
:1. Introduction
2. Results
2.1. Study Population
2.2. Esketamine and Noresketamine Plasma Concentrations
3. Discussion
4. Materials and Methods
4.1. Design
4.2. Participants
4.3. Development of a Population Pharmacokinetic Model
4.4. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bozymski, K.M.; Crouse, E.L.; Titus-Lay, E.N.; Ott, C.A.; Nofziger, J.L.; Kirkwood, C.K. Esketamine: A Novel Option for Treatment-Resistant Depression. Ann Pharmacother. 2020, 54, 567–576. [Google Scholar] [CrossRef] [PubMed]
- McIntyre, R.S.; Rosenblat, J.D.; Nemeroff, C.B.; Sanacora, G.; Murrough, J.W.; Berk, M.; Brietzke, E.; Dodd, S.; Gorwood, P.; Ho, R.; et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am. J. Psychiatry 2021, 178, 383–399. [Google Scholar] [CrossRef] [PubMed]
- Havlik, J.L.; Wahid, S.; Teopiz, K.M.; McIntyre, R.S.; Krystal, J.H.; Rhee, T.G. Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023. Curr. Psychiatry Rep. 2024, 26, 176–213. [Google Scholar] [CrossRef]
- Zanos, P.; Gould, T.D. Mechanisms of ketamine action as an antidepressant. Mol. Psychiatry 2018, 23, 801–811. [Google Scholar] [CrossRef] [PubMed]
- Smith-Apeldoorn, S.Y.; Veraart, J.K.E.; Kamphuis, J.; van Asselt, A.D.I.; Touw, D.J.; Aan Het Rot, M.; Schoevers, R.A. Oral esketamine for treatment-resistant depression: Rationale and design of a randomized controlled trial. BMC Psychiatry 2019, 19, 375. [Google Scholar] [CrossRef]
- Meshkat, S.; Haikazian, S.; Di Vincenzo, J.D.; Fancy, F.; Johnson, D.; Chen-Li, D.; McIntyre, R.S.; Mansur, R.; Rosenblat, J.D. Oral ketamine for depression: An updated systematic review. World J. Biol. Psychiatry 2023, 24, 545–557. [Google Scholar] [CrossRef]
- Silberbauer, L.R.; Eggerstorfer, B.; Michenthaler, P.; Reichel, S.; Stimpfl, T.; Vanicek, T.; Naderi-Heiden, A.; Kasper, S.; Lanzenberger, R.; Gryglewski, G. Oral Ketamine for the Treatment of Depression: A randomized controlled trial and meta-analysis. medRxiv 2025. [Google Scholar] [CrossRef]
- Langmia, I.M.; Just, K.S.; Yamoune, S.; Müller, J.P.; Stingl, J.C. Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant—Implications for precision dosing in a global perspective. Br. J. Clin. Pharmacol. 2022, 88, 5149–5165. [Google Scholar] [CrossRef]
- Daly, E.J.; Singh, J.B.; Fedgchin, M.; Cooper, K.; Lim, P.; Shelton, R.C.; Thase, M.E.; Winokur, A.; Van Nueten, L.; Manji, H.; et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2018, 75, 139–148. [Google Scholar] [CrossRef]
- Zaki, N.; Chen, L.N.; Lane, R.; Doherty, T.; Drevets, W.C.; Morrison, R.L.; Sanacora, G.; Wilkinson, S.T.; Popova, V.; Fu, D.J. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: Interim results of the SUSTAIN-3 study. Neuropsychopharmacology 2023, 48, 1225–1233. [Google Scholar] [CrossRef]
- Smith-Apeldoorn, S.Y.; Veraart, J.K.; Spijker, J.; Kamphuis, J.; Schoevers, R.A. Maintenance ketamine treatment for depression: A systematic review of efficacy, safety, and tolerability. Lancet Psychiatry 2022, 9, 907–921. [Google Scholar] [CrossRef]
- Wajs, E.; Aluisio, L.; Holder, R.; Daly, E.J.; Lane, R.; Lim, P.; George, J.E.; Morrison, R.L.; Sanacora, G.; Young, A.H.; et al. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). J. Clin. Psychiatry 2020, 81, 10773. [Google Scholar] [CrossRef]
- Daly, E.J.; Trivedi, M.H.; Janik, A.; Li, H.; Zhang, Y.; Li, X.; Lane, R.; Lim, P.; Duca, A.R.; Hough, D.; et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2019, 76, 893–903. [Google Scholar] [CrossRef] [PubMed]
- Fedgchin, M.; Trivedi, M.; Daly, E.J.; Melkote, R.; Lane, R.; Lim, P.; Vitagliano, D.; Blier, P.; Fava, M.; Liebowitz, M.; et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int. J. Neuropsychopharmacol. 2019, 22, 616–630. [Google Scholar] [CrossRef] [PubMed]
- Morgan, C.J.; Rees, H.; Curran, H.V. Attentional bias to incentive stimuli in frequent ketamine users. Psychol. Med. 2008, 38, 1331–1340. [Google Scholar] [CrossRef] [PubMed]
- Livingston, A.; Waterman, A.E. The development of tolerance to ketamine in rats and the significance of hepatic metabolism. Br. J. Pharmacol. 1978, 64, 63–69. [Google Scholar] [CrossRef]
- Hakkola, J.; Hukkanen, J.; Turpeinen, M.; Pelkonen, O. Inhibition and induction of CYP enzymes in humans: An update. Arch. Toxicol. 2020, 94, 3671–3722. [Google Scholar] [CrossRef]
- Marietta, M.P.; White, P.F.; Pudwill, C.R.; Way, W.L.; Trevor, A.J. Biodisposition of ketamine in the rat: Self-induction of metabolism. J. Pharmacol. Exp. Ther. 1976, 196, 536–544. [Google Scholar] [CrossRef]
- Livingston, A.; Waterman, A.E. Self induction of metabolism by ketamine in the rat [proceedings]. Br. J. Pharmacol. 1977, 60, 296–297. [Google Scholar]
- Chan, W.H.; Sun, W.Z.; Ueng, T.H. Induction of rat hepatic cytochrome P-450 by ketamine and its toxicological implications. J. Toxicol. Environ. Health A 2005, 68, 1581–1597. [Google Scholar] [CrossRef]
- Lin, F.; He, Y.; Zhang, L.; Zhang, M.; Zhang, Y.; Wen, C. Assessment of the effect of ketamine on cytochrome P450 isoforms activity in rats by cocktail method. Int. J. Clin. Exp. Med. 2015, 8, 4335–4341. [Google Scholar] [PubMed]
- Glue, P.; Medlicott, N.J.; Surman, P.; Lam, F.; Hung, N.; Hung, C.T. Ascending-Dose Study of Controlled-Release Ketamine Tablets in Healthy Volunteers: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability. J. Clin. Pharmacol. 2020, 60, 751–757. [Google Scholar] [CrossRef]
- Glue, P.; Medlicott, N.J.; Neehoff, S.; Surman, P.; Lam, F.; Hung, N.; Hung, C.T. Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: Open label pilot study. Ther. Adv. Psychopharmacol. 2020, 10, 2045125320922474. [Google Scholar] [CrossRef]
- Khan, M.S.; Bhatti, A.H. Ketamine tolerance. Postgrad. Med. J. 1988, 64, 833–834. [Google Scholar] [CrossRef]
- MacLennan, F.M. Ketamine tolerance and hallucinations in children. Anaesthesia 1982, 37, 1214–1215. [Google Scholar] [CrossRef] [PubMed]
- Villanueva-Perez, V.L.; Cerdá-Olmedo, G.; Samper, J.M.; Mínguez, A.; Monsalve, V.; Bayona, M.J.; De Andrés, J.A. Oral ketamine for the treatment of type I complex regional pain syndrome. Pain Pract. 2007, 7, 39–43. [Google Scholar] [CrossRef] [PubMed]
- Pal, H.R.; Berry, N.; Kumar, R.; Ray, R. Ketamine dependence. Anaesth. Intensive Care 2002, 30, 382–384. [Google Scholar] [CrossRef]
- Goyal, S.; Ambekar, A.; Ray, R. Ketamine dependence in an anesthesiologist: An occupational hazard? Indian J. Psychol. Med. 2014, 36, 335–337. [Google Scholar] [CrossRef]
- Critchlow, D.G. A case of ketamine dependence with discontinuation symptoms. Addiction 2006, 101, 1212–1213. [Google Scholar] [CrossRef]
- Moore, N.N.; Bostwick, J.M. Ketamine dependence in anesthesia providers. Psychosomatics 1999, 40, 356–359. [Google Scholar] [CrossRef]
- Huang, M.C.; Chen, L.Y.; Chang, H.M.; Liang, X.Y.; Chen, C.K.; Cheng, W.J.; Xu, K. Decreased Blood Levels of Oxytocin in Ketamine-Dependent Patients During Early Abstinence. Front. Psychiatry 2018, 9, 633. [Google Scholar] [CrossRef]
- Smith-Apeldoorn, S.Y.; Veraart, J.K.E.; Kamphuis, J.; Spijker, J.; van der Meij, A.; van Asselt, A.D.I.; Aan Het Rot, M.; Schoevers, R.A. Oral esketamine in patients with treatment-resistant depression: A double-blind, randomized, placebo-controlled trial with open-label extension. Mol. Psychiatry 2024, 29, 2657–2665. [Google Scholar] [CrossRef]
- Veraart, J.K.; Smith-Apeldoorn, S.Y.; van der Meij, A.; Spijker, J.; Schoevers, R.A.; Kamphuis, J. Oral esketamine for patients with severe treatment-resistant depression. Effectiveness, safety, and tolerability of a six-week open-label treatment program. J. Psychopharmacol. 2025; accepted for publication. [Google Scholar]
- Spravato. Assessment Report EMA/614876/2019, EMA Committee for Medicinal Products for Human Use (CHMP), 21 November 2019. Spravato, INN-Esketamine Date 30 December 2024. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/spravato (accessed on 30 December 2024).
- Han, X.M.; Ouyang, D.S.; Chen, X.P.; Shu, Y.; Jiang, C.H.; Tan, Z.R.; Zhou, H.H. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br. J. Clin. Pharmacol. 2002, 54, 540–543. [Google Scholar] [CrossRef] [PubMed]
- Ho, M.F.; Correia, C.; Ingle, J.N.; Kaddurah-Daouk, R.; Wang, L.; Kaufmann, S.H.; Weinshilboum, R.M. Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. Biochem. Pharmacol. 2018, 152, 279–292. [Google Scholar] [CrossRef] [PubMed]
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders; American Psychiatric Association: Washington, DC, USA, 2013. [Google Scholar]
- Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23, 56–62. [Google Scholar] [CrossRef]
- Kamp, J.; Jonkman, K.; van Velzen, M.; Aarts, L.; Niesters, M.; Dahan, A.; Olofsen, E. Pharmacokinetics of ketamine and its major metabolites norketamine, hydroxynorketamine, and dehydronorketamine: A model-based analysis. Br. J. Anaesth. 2020, 125, 750–761. [Google Scholar] [CrossRef]
- Fanta, S.; Kinnunen, M.; Backman, J.T.; Kalso, E. Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur. J. Clin. Pharmacol. 2015, 71, 441–447. [Google Scholar] [CrossRef]
- Zhao, X.; Venkata, S.L.; Moaddel, R.; Luckenbaugh, D.A.; Brutsche, N.E.; Ibrahim, L.; Zarate, C.A., Jr.; Mager, D.E.; Wainer, I.W. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br. J. Clin. Pharmacol. 2012, 74, 304–314. [Google Scholar] [CrossRef]
- Weiss, M.; Siegmund, W. Pharmacokinetic Modeling of Ketamine Enantiomers and Their Metabolites After Administration of Prolonged-Release Ketamine With Emphasis on 2,6-Hydroxynorketamines. Clin. Pharmacol. Drug Dev. 2022, 11, 194–206. [Google Scholar] [CrossRef]
- Perez-Ruixo, C.; Rossenu, S.; Zannikos, P.; Nandy, P.; Singh, J.; Drevets, W.C.; Perez-Ruixo, J.J. Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. Clin. Pharmacokinet. 2021, 60, 501–516. [Google Scholar] [CrossRef] [PubMed]
- Rozenveld, E.; Punt, N.; van Faassen, M.; van Beek, A.P.; Touw, D.J. Pharmacokinetic Modeling of Hydrocortisone by Including Protein Binding to Corticosteroid-Binding Globulin. Pharmaceutics 2022, 14, 1161. [Google Scholar] [CrossRef] [PubMed]
- van den Born, D.A.; Märtson, A.G.; Veringa, A.; Punt, N.C.; van der Werf, T.S.; Alffenaar, J.C.; Sturkenboom, M.G.G.; Touw, D.J. Voriconazole exposure is influenced by inflammation: A population pharmacokinetic model. Int. J. Antimicrob. Agents 2023, 61, 106750. [Google Scholar] [CrossRef] [PubMed]
- Abolhassani-Chimeh, R.; Akkerman, O.W.; Saktiawati, A.M.I.; Punt, N.C.; Bolhuis, M.S.; Subronto, Y.W.; Sumardi van der Werf, T.S.; Kosterink, J.G.W.; Alffenaar, J.C.; Sturkenboom, M.G.G. Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis. Antimicrob. Agents Chemother. 2022, 66, e0000322. [Google Scholar] [CrossRef]
- IBM Corp. IBM SPSS Statistics for Windows, Version 30; IBM Corp: Armonk, NY, USA, 2024.
- Vos, C.F.; Hemminga, W.L.; Aarnoutse, R.E.; Ruhé, H.G. Increasing the bioavailability of oral esketamine by a single dose of cobicistat: A case study. Pharmacotherapy 2024, 44, 480–484. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Veraart, J.K.E.; Vos, C.F.; Punt, N.C.; Visser, D.; Wessels, M.A.; Smith-Apeldoorn, S.Y.; Kamphuis, J.; Schoevers, R.A.; Touw, D.J. Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study. Pharmaceuticals 2025, 18, 627. https://doi.org/10.3390/ph18050627
Veraart JKE, Vos CF, Punt NC, Visser D, Wessels MA, Smith-Apeldoorn SY, Kamphuis J, Schoevers RA, Touw DJ. Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study. Pharmaceuticals. 2025; 18(5):627. https://doi.org/10.3390/ph18050627
Chicago/Turabian StyleVeraart, Jolien K. E., Cornelis F. Vos, Nieko C. Punt, Dylan Visser, Mireille A. Wessels, Sanne Y. Smith-Apeldoorn, Jeanine Kamphuis, Robert A. Schoevers, and Daan J. Touw. 2025. "Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study" Pharmaceuticals 18, no. 5: 627. https://doi.org/10.3390/ph18050627
APA StyleVeraart, J. K. E., Vos, C. F., Punt, N. C., Visser, D., Wessels, M. A., Smith-Apeldoorn, S. Y., Kamphuis, J., Schoevers, R. A., & Touw, D. J. (2025). Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study. Pharmaceuticals, 18(5), 627. https://doi.org/10.3390/ph18050627